Dilpacimab
Based on 1 Customer Validation
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors.
For research use only. We do not sell to patients.
- Purity: 96.88%
- CAS No.: 1791420-09-1
- Molecular Weight:199.12 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer
Human
VEGFA & DLL4
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer
ELISA, FACS, Functional assay
-
Immobilized Delta-like protein 4/DLL4 Protein, Human can bind Dilpacimab. The EC50 for this effect is 5.82 ng/mL. -
Flow cytometric analysis of 1X106 HeLa cells with Dilpacimab (HY-P99852, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1791420-09-1
-
Appearance Liquid
-
Molecular Weight 199.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Dilpacimab]
-
Synonyms
ABT165; PR1283233
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Strickler JH, et al. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022;18(27):3011-3020. [Content Brief]
[2]. Gordon MS, et al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021;20(10):1988-1995. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)